Kehua Bio-Engineering subsidiary secures HPV diagnostic kit registration

Shanghai Kehua Bio-Engineering’s subsidiary, Suzhou Tianlong Bio-technology Co. Ltd., has received a medical device registration certificate for its human papillomavirus (HPV) nucleic acid genotyping kit (fluorescent PCR method). The certificate is valid from August 25, 2025, to August 24, 2030.

This kit is designed for in vitro qualitative detection and genotyping of 21 HPV types in female cervical exfoliate cells. The company expects this new product to enrich its offerings and positively impact business development, though its immediate effect on future revenue is not yet estimable.

Kehua Bio-Engineering also disclosed its half-yearly report and a special report on the storage and use of raised funds for the first half of 2025. These reports, approved by the board and supervisory board on August 25, 2025, confirm compliance with relevant laws and regulations and an absence of false records or significant omissions. The raised funds report confirms no changes in the use of funds or project implementation within the reporting period.